Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

19.140
+0.3701.97%
Volume:7.33M
Turnover:138.24M
Market Cap:21.78B
PE:-15.23
High:19.250
Open:18.680
Low:18.650
Close:18.770
52wk High:27.280
52wk Low:12.310
Shares:1.14B
HK Float Shares:1.14B
Volume Ratio:2.38
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.257
ROE:-26.91%
ROA:-14.75%
PB:4.58
PE(LYR):-15.23
PS:6.18

Loading ...

Zai Lab, Boehringer Ingelheim team up on DLL3 combo trial in lung cancer

Reuters
·
Apr 15

Boehringer Ingelheim and Zai Lab Announce Collaboration on Dll3‑Targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

THOMSON REUTERS
·
Apr 15

Zai Lab Ltd: Under Agreement, Co to Supply Dll3‑Targeting ADC for Study, Boehringer to Sponsor & Oversee Day‑to‑Day Clinical Operations

THOMSON REUTERS
·
Apr 15

Zai Lab Shares Climb Over 3% Following Global Clinical Partnership with Amgen for Zoci Candidate

Stock News
·
Apr 14

Zai Lab Boosts Issued Share Base by 6.00 Million in March; Public Float Remains Above 25%

Bulletin Express
·
Apr 08

Zai Lab Grants Stock Options, Restricted Share Units, and Performance Share Units

Stock News
·
Apr 02

Zai Lab grants equity awards covering 9 million shares under 2024 incentive plan

Reuters
·
Apr 02

Zai Lab Rises Nearly 5% in Morning Session Following Global Clinical Research Collaboration with Amgen

Deep News
·
Apr 02

Stock Track | Zai Lab Soars 5.94% Intraday on Clinical Partnership with Amgen for Lung Cancer Treatment

Stock Track
·
Apr 02

Zai Lab Shares Climb Over 4% Following Global Clinical Partnership with Amgen for Small Cell Lung Cancer Treatment

Stock News
·
Apr 02

Asian Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading

MT Newswires Live
·
Apr 01

BRIEF-Zai Lab Announces Global Clinical Trial Collaboration And Supply Agreement To Evaluate Novel Dll3 Adc, Zocilurtatug Pelitecan, In Combination With A Bispecific T-Cell Engager Therapy

Reuters
·
Apr 01

Zai Lab, Amgen partner on global trial of DLL3 ADC with Imdelltra in SCLC

Reuters
·
Apr 01

Zai Lab Ltd - Announces Global Clinical Trial Collaboration With Amgen for Es-Sclc

THOMSON REUTERS
·
Apr 01

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Dll3 ADC, Zocilurtatug Pelitecan, in Combination With a Bispecific T-Cell Engager Therapy

THOMSON REUTERS
·
Apr 01

Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director

Reuters
·
Mar 27

Zai Lab files next day disclosure return with Hong Kong Stock Exchange; share capital rises by 6,000,000 shares at HKD 0

Reuters
·
Mar 27

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress
·
Mar 27

Zai Lab's 2025 Loss Narrows by 32% as Revenue Jumps 15%

MT Newswires Live
·
Mar 27

Zai Lab Reports Fiscal Year Results with 15% Revenue Growth to $460 Million and Positive Pipeline Updates

Stock News
·
Mar 27